Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy

Cancer of Cervix Clinical Trial

— HSTH  

Official title:

Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04809727
• Other study ID #: HistopathSTH
• Status: Completed
• Phase: N/A
• Start date: December 1, 2017
• Est. completion date: January 31, 2021

Study information

• Verified date: April 2021
• Source: Tanta University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Supracervical hysterectomy is widely common and had many complications either immediate or delayed. In these patients bleeding, infection, chronic pelvic pain are common. In these patients cervical biopsy was done and histopathological examinations were done to evaluate the pathology in these patients.

Description:

• Study design and settings: Cross sectional descriptive studies conducted from December 2017 till January 2021.

• Patients: 80 patients with supracervical hysterectomy recruited at Tanta University Hospital, gynecology clinics will be recruited according inclusion and exclusion criteria. Inclusion criteria include all symptomatizing patients following supracervical hysterectomy, of any age, of any complaints. The exclusion criteria were patients with total hysterectomy, hysterectomies for malignant indications, and refusal to participate.

• Methods: All patients' demographic data, history, indication of hysterectomy, duration since operation, postoperative complications and their main complaint.

Intervention: under general anesthesia cervical biopsy (4 quadrants) were taken from all patients and was sent for histopathological examinations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 88
• Est. completion date: January 31, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• all symptomatizing patients following supracervical hysterectomy,

Exclusion Criteria:

• with total hysterectomy,

• hysterectomies for malignant indications,

• refusal to participate.

Related Conditions & MeSH terms

• Cancer of Cervix
• Cervicitis
• CIN
• Uterine Cervical Neoplasms
• Uterine Cervicitis

Intervention

Procedure:
• Cervical biopsy
4 quadrant biopsy

Locations

Country	Name	City	State
Egypt	Ayman Shehata Dawood	Tanta	Gharbia

Sponsors (1)

Lead Sponsor	Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection of cervical neoplasia or cancer incidence	Detection of number of cases diagnosed with cervical Cervical intraepithelial neoplasia, or malignancy by histopathological examination	1 year
Primary	Detection of chronic cervicitis incidence	Detection of number of cases diagnosed with inflammatory cells and other markers of inflammation	1 year